# ICU Medical Inc: financial statements, quarterly ICUI · Nasdaq · CIK 883984 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/icui.md) · [Financials](/companies/icui/financials.md) · [Filings](/companies/icui/filings.md) · [Insiders](/companies/icui/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/icui/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [553](/filings/0000883984-24-000042.md) | [588 d](/filings/0000883984-26-000008.md) | [567](/filings/0000883984-25-000016.md) | [596](/filings/0000883984-25-000030.md) | [589](/filings/0000883984-25-000035.md) | [630 d](/filings/0000883984-26-000008.md) | [605](/filings/0000883984-26-000029.md) | [549](/filings/0000883984-26-000041.md) | [537](/filings/0000883984-25-000035.md) | [541 d](/filings/0000883984-26-000008.md) | [530](/filings/0000883984-26-000029.md) | [552](/filings/0000883984-26-000041.md) | | Cost of revenue | $m | [369](/filings/0000883984-24-000042.md) | [416 d](/filings/0000883984-26-000008.md) | [381](/filings/0000883984-25-000016.md) | [389](/filings/0000883984-25-000030.md) | [384](/filings/0000883984-25-000035.md) | [403 d](/filings/0000883984-26-000008.md) | [395](/filings/0000883984-26-000029.md) | [341](/filings/0000883984-26-000041.md) | [336](/filings/0000883984-25-000035.md) | [338 d](/filings/0000883984-26-000008.md) | [324](/filings/0000883984-26-000029.md) | [317](/filings/0000883984-26-000041.md) | | Gross profit | $m | [184](/filings/0000883984-24-000042.md) | [172 d](/filings/0000883984-26-000008.md) | [185](/filings/0000883984-25-000016.md) | [207](/filings/0000883984-25-000030.md) | [205](/filings/0000883984-25-000035.md) | [227 d](/filings/0000883984-26-000008.md) | [210](/filings/0000883984-26-000029.md) | [208](/filings/0000883984-26-000041.md) | [201](/filings/0000883984-25-000035.md) | [203 d](/filings/0000883984-26-000008.md) | [206](/filings/0000883984-26-000029.md) | [235](/filings/0000883984-26-000041.md) | | Research and development | $m | [20.9](/filings/0000883984-24-000042.md) | [22.4 d](/filings/0000883984-26-000008.md) | [21.8](/filings/0000883984-25-000016.md) | [23.4](/filings/0000883984-25-000030.md) | [21.0](/filings/0000883984-25-000035.md) | [22.4 d](/filings/0000883984-26-000008.md) | [23.3](/filings/0000883984-26-000029.md) | [21.9](/filings/0000883984-26-000041.md) | [21.3](/filings/0000883984-25-000035.md) | [21.1 d](/filings/0000883984-26-000008.md) | [21.3](/filings/0000883984-26-000029.md) | [22.7](/filings/0000883984-26-000041.md) | | Selling, general and administrative | $m | [149](/filings/0000883984-24-000042.md) | [155 d](/filings/0000883984-26-000008.md) | [158](/filings/0000883984-25-000016.md) | [160](/filings/0000883984-25-000030.md) | [163](/filings/0000883984-25-000035.md) | [159 d](/filings/0000883984-26-000008.md) | [157](/filings/0000883984-26-000029.md) | [159](/filings/0000883984-26-000041.md) | [153](/filings/0000883984-25-000035.md) | [156 d](/filings/0000883984-26-000008.md) | [155](/filings/0000883984-26-000029.md) | [152](/filings/0000883984-26-000041.md) | | Operating income | $m | [22.9](/filings/0000883984-24-000042.md) | [(12.2) d](/filings/0000883984-26-000008.md) | [(10.7)](/filings/0000883984-25-000016.md) | [7.7](/filings/0000883984-25-000030.md) | [8.2](/filings/0000883984-25-000035.md) | [37.7 d](/filings/0000883984-26-000008.md) | [12.9](/filings/0000883984-26-000029.md) | [10.6](/filings/0000883984-26-000041.md) | [13.7](/filings/0000883984-25-000035.md) | [5.6 d](/filings/0000883984-26-000008.md) | [13.6](/filings/0000883984-26-000029.md) | [39.1](/filings/0000883984-26-000041.md) | | Interest expense | $m | [24.2](/filings/0000883984-24-000042.md) | [31.9 d](/filings/0000883984-26-000008.md) | [23.8](/filings/0000883984-25-000016.md) | [23.8](/filings/0000883984-25-000030.md) | [24.7](/filings/0000883984-25-000035.md) | [34.2 d](/filings/0000883984-26-000008.md) | [22.0](/filings/0000883984-26-000029.md) | [20.5](/filings/0000883984-26-000041.md) | [19.8](/filings/0000883984-25-000035.md) | [31.0 d](/filings/0000883984-26-000008.md) | [16.5](/filings/0000883984-26-000029.md) | [15.7](/filings/0000883984-26-000041.md) | | Income tax | $m | [(12.6)](/filings/0000883984-24-000042.md) | [(19.5) d](/filings/0000883984-26-000008.md) | [2.7](/filings/0000883984-25-000016.md) | [1.9](/filings/0000883984-25-000030.md) | [15.1](/filings/0000883984-25-000035.md) | [32.0 d](/filings/0000883984-26-000008.md) | [4.6](/filings/0000883984-26-000029.md) | [1.2](/filings/0000883984-26-000041.md) | [(0.7)](/filings/0000883984-25-000035.md) | [(2.7) d](/filings/0000883984-26-000008.md) | [(34.7)](/filings/0000883984-26-000029.md) | [7.1](/filings/0000883984-26-000041.md) | | Net income | $m | [7.2](/filings/0000883984-24-000042.md) | [(17.1) d](/filings/0000883984-26-000008.md) | [(39.5)](/filings/0000883984-25-000035.md) | [(21.4)](/filings/0000883984-25-000035.md) | [(33.0)](/filings/0000883984-25-000035.md) | [(23.8) d](/filings/0000883984-26-000008.md) | [(15.5)](/filings/0000883984-26-000041.md) | [35.3](/filings/0000883984-26-000041.md) | [(3.4)](/filings/0000883984-25-000035.md) | [(15.7) d](/filings/0000883984-26-000008.md) | [30.1](/filings/0000883984-26-000041.md) | [19.1](/filings/0000883984-26-000041.md) | | Diluted EPS | $ per share | [0.30](/filings/0000883984-24-000042.md) | not reported | [(1.63)](/filings/0000883984-25-000016.md) | [(0.88)](/filings/0000883984-25-000030.md) | [(1.35)](/filings/0000883984-25-000035.md) | not reported | [(0.63)](/filings/0000883984-26-000029.md) | [1.43](/filings/0000883984-26-000041.md) | [(0.14)](/filings/0000883984-25-000035.md) | not reported | [1.20](/filings/0000883984-26-000029.md) | [0.76](/filings/0000883984-26-000041.md) | | Basic EPS | $ per share | [0.30](/filings/0000883984-24-000042.md) | not reported | [(1.63)](/filings/0000883984-25-000016.md) | [(0.88)](/filings/0000883984-25-000030.md) | [(1.35)](/filings/0000883984-25-000035.md) | not reported | [(0.63)](/filings/0000883984-26-000029.md) | [1.43](/filings/0000883984-26-000041.md) | [(0.14)](/filings/0000883984-25-000035.md) | not reported | [1.22](/filings/0000883984-26-000029.md) | [0.76](/filings/0000883984-26-000041.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues - Cost of revenue: us-gaap:CostOfRevenue, us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current assets | $m | [1,219](/filings/0000883984-23-000038.md) | [1,221](/filings/0000883984-25-000007.md) | [1,188](/filings/0000883984-24-000016.md) | [1,236](/filings/0000883984-24-000030.md) | [1,258](/filings/0000883984-24-000042.md) | [1,442](/filings/0000883984-26-000008.md) | [1,424](/filings/0000883984-25-000016.md) | [1,180](/filings/0000883984-25-000030.md) | [1,207](/filings/0000883984-25-000035.md) | [1,191](/filings/0000883984-26-000041.md) | [1,213](/filings/0000883984-26-000029.md) | [1,211](/filings/0000883984-26-000041.md) | | Total assets | $m | [4,377](/filings/0000883984-23-000038.md) | [4,378](/filings/0000883984-25-000007.md) | [4,288](/filings/0000883984-24-000016.md) | [4,287](/filings/0000883984-24-000030.md) | [4,305](/filings/0000883984-24-000042.md) | [4,204](/filings/0000883984-26-000008.md) | [4,185](/filings/0000883984-25-000016.md) | [4,107](/filings/0000883984-25-000030.md) | [4,103](/filings/0000883984-25-000035.md) | [4,051](/filings/0000883984-26-000041.md) | [4,014](/filings/0000883984-26-000029.md) | [3,971](/filings/0000883984-26-000041.md) | | Current liabilities | $m | [464](/filings/0000883984-23-000038.md) | [482](/filings/0000883984-25-000007.md) | [455](/filings/0000883984-24-000016.md) | [512](/filings/0000883984-24-000030.md) | [550](/filings/0000883984-24-000042.md) | [556](/filings/0000883984-26-000008.md) | [549](/filings/0000883984-25-000016.md) | [483](/filings/0000883984-25-000030.md) | [493](/filings/0000883984-25-000035.md) | [499](/filings/0000883984-26-000041.md) | [518](/filings/0000883984-26-000029.md) | [498](/filings/0000883984-26-000041.md) | | Long-term debt | $m | [1,589](/filings/0000883984-23-000038.md) | [1,578](/filings/0000883984-25-000007.md) | [1,566](/filings/0000883984-24-000016.md) | [1,555](/filings/0000883984-24-000030.md) | [1,543](/filings/0000883984-24-000042.md) | [1,532](/filings/0000883984-26-000008.md) | [1,489](/filings/0000883984-25-000016.md) | [1,338](/filings/0000883984-25-000030.md) | [1,314](/filings/0000883984-25-000035.md) | [1,266](/filings/0000883984-26-000041.md) | [1,262](/filings/0000883984-26-000029.md) | [1,212](/filings/0000883984-26-000041.md) | | Current portion of debt | $m | [45.7](/filings/0000883984-23-000038.md) | [51.0](/filings/0000883984-25-000007.md) | [51.0](/filings/0000883984-24-000016.md) | [51.0](/filings/0000883984-24-000030.md) | [51.0](/filings/0000883984-24-000042.md) | [51.0](/filings/0000883984-26-000008.md) | [47.8](/filings/0000883984-25-000016.md) | [0.0](/filings/0000883984-25-000030.md) | [0.0](/filings/0000883984-25-000035.md) | [18.8](/filings/0000883984-26-000041.md) | [18.8](/filings/0000883984-26-000029.md) | [18.8](/filings/0000883984-26-000041.md) | | Shareholders' equity | $m | [2,098](/filings/0000883984-24-000042.md) | [2,123](/filings/0000883984-26-000008.md) | [2,068](/filings/0000883984-25-000035.md) | [2,038](/filings/0000883984-25-000035.md) | [2,049](/filings/0000883984-25-000035.md) | [1,965](/filings/0000883984-26-000041.md) | [1,988](/filings/0000883984-26-000041.md) | [2,116](/filings/0000883984-26-000041.md) | [2,127](/filings/0000883984-25-000035.md) | [2,124](/filings/0000883984-26-000041.md) | [2,112](/filings/0000883984-26-000041.md) | [2,152](/filings/0000883984-26-000041.md) | - Cash and equivalents: not reported - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [35.2 d](/filings/0000883984-24-000042.md) | [91.3 d](/filings/0000883984-26-000008.md) | [45.8](/filings/0000883984-25-000016.md) | [82.0 d](/filings/0000883984-25-000030.md) | [36.1 d](/filings/0000883984-25-000035.md) | [40.2 d](/filings/0000883984-26-000008.md) | [51.3](/filings/0000883984-26-000029.md) | [11.2 d](/filings/0000883984-26-000041.md) | [56.7 d](/filings/0000883984-25-000035.md) | [60.6 d](/filings/0000883984-26-000008.md) | [38.9](/filings/0000883984-26-000029.md) | [80.2 d](/filings/0000883984-26-000041.md) | | Capital expenditure | $m | [21.5 d](/filings/0000883984-24-000042.md) | [29.9 d](/filings/0000883984-26-000008.md) | [15.9](/filings/0000883984-25-000016.md) | [19.5 d](/filings/0000883984-25-000030.md) | [19.9 d](/filings/0000883984-25-000035.md) | [24.1 d](/filings/0000883984-26-000008.md) | [14.6](/filings/0000883984-26-000029.md) | [19.7 d](/filings/0000883984-26-000041.md) | [29.1 d](/filings/0000883984-25-000035.md) | [24.6 d](/filings/0000883984-26-000008.md) | [11.3](/filings/0000883984-26-000029.md) | [18.5 d](/filings/0000883984-26-000041.md) | | Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: not reported ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [23.9](/filings/0000883984-23-000038.md) | [24.0](/filings/0000883984-24-000016.md) | [24.1](/filings/0000883984-24-000030.md) | [24.4](/filings/0000883984-24-000042.md) | [24.2](/filings/0000883984-25-000016.md) | [24.4](/filings/0000883984-25-000030.md) | [24.4](/filings/0000883984-25-000035.md) | [24.5](/filings/0000883984-26-000029.md) | [24.7](/filings/0000883984-26-000041.md) | [24.7](/filings/0000883984-25-000035.md) | [25.2](/filings/0000883984-26-000029.md) | [25.0](/filings/0000883984-26-000041.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 25,007,038 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0000883984-26-000041.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.